Where can I get that gene “juice”?

By Abby Larson

Athletes are competitive by nature, and many will do whatever they can to win.  Steroid usage is heavily monitored in competitions, yet with the coming of the Winter Olympics, whispers of “gene doping” are becoming audible. There has been a craze by athletes for “gene juice” ever since a 2005 study performed by Dr. Ronald Evans, a geneticist at the Salk Institute for Biological Studies in San Diego, California, produced the “Marathon Mouse”.  Evans discovered a gene involved in muscle formation and altered it, producing a mouse that could run twice as far as normal mice.  This spurred the World Anti-Doping Agency (WADA) to list gene doping as illegal.

Evans was searching for a way to treat muscular dystrophy, characterized by muscle wasting and inability to build muscle.  His study was based on the idea of gene therapy: treating a disease caused by a mutated or malfunctioning gene by inserting copies of the normal gene into cells.  The cells essentially replace the non-functional gene with the normal one.  So, if you can use gene therapy to treat mutated genes, why can’t you use gene therapy to replace a “normal” athletic gene with a “high performance” athletic gene?

A review article by Dr. Craig Sharp that will be published in March, 2010, titled “The Human Genome and Sport, Including Epigenetics, Gene Doping, and Athleticogenomics,” discusses many athletic performance gene discoveries that may be possible targets for gene doping.   One example is a gene encoding myostatin, an inhibitor of muscle growth.  Exercise tears muscles, which results in increased expression of actin and myosin.  This increase in expression is eventually repressed by the protein myostatin, preventing excessive muscle growth.  In 2004, a boy was born with a mutated form of myostatin that disrupted some of the protein’s function.  The boy had significantly hypertrophied muscles, and was still unusually muscular at age 4.  Based on studies like this one, by injecting muscle cells with the mutated form of myostatin, Sharp believes that athletes and bodybuilders can create greater muscle mass than without the gene doping because inhibition of muscle production will be decreased following exercise.  Who knew genetic studies could lead to Schwarzenegger-sized people?

Death does not seem to scare overzealous coaches and athletes, who may bypass the risks of gene doping to achieve that extra edge.  In several gene therapy studies, some patients developed cancers or severe autoimmune responses to the product of the injected genes.  A 2008 report by Dr. E.B. Wheeldon showed that a patient went into an extreme immune response due to a reaction with a carrier virus used to transmit the gene of interest into his cells, causing death from organ failure.  This does not seem to discourage some athletes and coaches.

Have athletes started using gene doping to get ahead?  An experimental drug, Repoxygen, was developed to treat severe anemia due to a mutated gene.  As several Olympic coaches discovered, Repoxygen contained the gene for erythropoietin (EPO), which increases red blood cell production and performance.  EPO itself is a currently banned substance by WADA for performance enhancement—but how can one detect the gene for it?  There are no current established methods for gene doping detection aside from muscle biopsy, says Sharp, which is a painful and unappealing method of detecting changes in tissue development.  A rising technique commonly used in cancer genomics may be the key: DNA microarray.  A DNA microarray detects changes in gene expression in a person between two periods in time.  In order for anti-doping agencies to use this method in top competitions such as the Olympics, an athlete’s genetic file must be established as a reference.  WADA has already developed a “passport” program to keep blood and urine samples of athletes on file to use for future genomic comparisons.

Gene doping raises an ethical issue that surpasses steroid use due to its difficulty in detection, although gene doping has been banned for over 5 years for major competitions.  By the 2012 Summer Olympics in London, genetic testing could be a common procedure by anti-doping committees.  It seems that as we learn more about the way the body responds to exercise and why the world’s top athletes are so good, more daemons are unleashed from Pandora’s box.

Not Your Average Fairytale

By Kristen Kocher                        February 4, 2010

Numerous genetic diseases, especially hereditary brain diseases, are untreatable therefore subjecting many individuals to a life of endless pain and suffering. However, in recent years with the development of the technique of gene therapy, new hope has been brought to life in those diagnosed as “terminally ill” with the promise of the “happily ever after” ending that everyone deserves.

Gene therapy is still not used as a mainstream medical technique because much of the process is still in the developmental stages. Recently, geneticists have been desperately working to perfect the successful transport of therapy genes into brain cells. In many cases, the diseases are caused by a single gene or protein mutation but can cause devastating affects, which normally result in the loss of brain cells and fatality.

A recent scientific breakthrough has finally made it possible for therapy genes to be inserted into brain cells and cure certain genetic diseases.  Before this discovery, therapy genes were only administered through the use of viruses, predominantly the herpes virus, HSV-1. While HSV-1 has the ability to effectively transport large genes into the nucleus of the targeted cells, once the genetic information enters the nucleus it is unable to be integrated into the mammalian, host genome. This proves to be unhelpful as the therapeutic information is quickly silenced and within a few days the effects of gene therapy are no longer visible.  

Another molecule used for gene therapy transport is known as “Sleeping Beauty”. The aforementioned molecule is named as such because it is innately a silent gene that was activated, or “awakened”, by scientists. The discovery of this molecule is beneficial because it has the ability to take the target gene intended for therapy into the nucleus and integrate it directly into the mammalian genome.  The genes transported by Sleeping Beauty, however, must be relatively small, roughly 15 to 30 times less than the amount of DNA carried by HSV-1. This is unfortunate because the genes that are used for treatment of diseased brain cells are predominately large and cannot be carried by Sleeping Beauty.

So, where does the happy ending come in? These two molecules individually have characteristics that make them useful in therapy gene transport but separately cannot aid in the treatment of brain disease. However, thanks to the research of William Bowers, Ph.D. and graduate student Suresh de Silva, this blockade has been removed. With the creation of a hybrid molecule made up of both HSV-1 and Sleeping Beauty, geneticists have been able to successfully integrate large therapy genes into the mammalian genome, which, though current experiments, have resulted in long-term therapeutic gene expression. The creation of this hybrid therapy gene transport molecule promises a bright future and “happy ending” for those suffering from terminal, genetic disease.

Original Press Release

Find out more about the projects going on in Bowers Laboratory